ライフサイエンスコーパス: bupropion

1 bupropion were more effective than switch to bupropion).

2 compared with placebo and 22% compared with bupropion.

3 A2A antagonist MSX-3 and the antidepressant bupropion.

4 enhanced under paroxetine and reduced under bupropion.

5 imary rewards (erotic videos), but not under bupropion.

6 T and [(3)H]NE uptake inhibition relative to bupropion.

7 as alleviated by fluoxetine, reboxetine, and bupropion.

8 conditions, this decrement was attenuated by bupropion.

9 ibute to the smoking-cessation properties of bupropion.

10 ylamine > dextromethorphan > or = ketamine > bupropion.

11 moking cessation medications varenicline and bupropion.

12 mg/kg/injection, FR10 schedule) during 7-day bupropion (0.32-1.8 mg/kg/h) and risperidone (0.001-0.00

13 4), nicotine patch (1.68, 1.46 to 1.93), and bupropion (1.75, 1.52 to 2.01).

14 , 25% [511 of 2016 participants]), insomnia (bupropion, 12% [245 of 2006 participants]), abnormal dre

15 trial of varenicline (1 mg twice a day) and bupropion (150 mg twice a day) for 12 weeks with 12-week

16 participants [29.8%]; naltrexone 16 mg plus bupropion, 155 [27.2%]; placebo, 30 [5.3%]).

17 rcent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline,

18 treatment was nausea (naltrexone 32 mg plus bupropion, 171 participants [29.8%]; naltrexone 16 mg pl

19 ssation were associated with NRT (17.6%) and bupropion (19.1%) compared with placebo (10.6%).

20 A series of bupropion (1a) analogues (1b-1ff) were synthesized, and

21 For bupropion, 2.77 kg (CI, 1.1 to 4.5 kg) of weight was los

22 drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400

23 ates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent

24 Bupropion (2a) analogues were synthesized and tested for

25 pants received open-label, sustained-release bupropion, 300 mg/d, for 7 weeks.

26 treatment were randomly assigned to receive bupropion, 300 mg/d, or placebo for 45 weeks and were su

27 trexone 32 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets

28 trexone 16 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets

29 placebo (n=4454) or naltrexone, 32 mg/d, and bupropion, 360 mg/d (n=4456).

30 kg (95% CrI, -6.06 to -4.52 kg); naltrexone-bupropion, 5.0 kg (95% CrI, -5.94 to -3.96 kg); lorcaser

31 for nicotine replacement treatment; 6557 for bupropion; 51,450 for varenicline) between Jan 1, 2007,

32 stat, 13 studies of fluoxetine, 5 studies of bupropion, 9 studies of topiramate, and 1 study each of

33 The results established that bupropion (a) inhibits epibatidine-induced Ca(2+) influx

34 Bupropion, a Food and Drug Administration-approved antid

35 oline receptor (nAChR) partial agonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor,

36 The primary mechanism of action of bupropion, a smoking cessation drug, is commonly believe

37 (OR=1.76; 95% CI: 1.23-2.52) (p<0.005); for bupropion, abstinence was associated with CYP2B6 (OR=1.7

38 f nicotine patch, nicotine oral inhaler, and bupropion ad libitum (n = 63).

39 cessing might be associated with response to bupropion after sertraline nonresponse.

40 y significantly improve outcomes relative to bupropion alone.

41 inergic system although evidence exists that bupropion also has effects at nicotinic acetylcholine re

42 investigate the effect of sustained-release bupropion (amfebutamone) (SR) in promoting abstinence fr

43 in A(1), a proton pump inhibitor, but not by bupropion, an inhibitor of the plasma membrane DA transp

44 rate ratio was 1.09 (95% CI, 0.75-1.59) for bupropion and 2.59 (95% CI, 1.56-4.30) for topiramate.

45 rate ratio was 1.98 (95% CI, 1.02-3.84) for bupropion and 5.30 (95% CI, 2.54-11.04) for topiramate.

46 ompared with those whose mothers were in the bupropion and combination treatment groups).

47 The effects of bupropion and enantiomers of hydroxybupropion on human n

48 The corresponding IC(50)s for bupropion and hydroxybupropion for homomeric 5-HT(3A)Rs

49 Racemic bupropion and hydroxybupropion inhibit [(3)H]norepinephr

50 crease DAT surface expression, we found that bupropion and ibogaine increased DAT surface expression,

51 Bupropion and ibogaine increased wild type DAT protein l

52 These data suggest that bupropion and ibogaine promote maturation of DAT by acti

53 type DAT, also blocked the rescue effects of bupropion and ibogaine.

54 tudy, we examined and compared the effect of bupropion and its active metabolite hydroxybupropion on

55 e effect curves were generated for nicotine, bupropion and mecamylamine.

56 0 years was twice as high in patients taking bupropion and more than 5 times higher in patients takin

57 Those on bupropion and nicotine patch achieved higher abstinence

58 helping smokers achieve abstinence, whereas bupropion and nicotine patch were more effective than pl

59 edications used to treat tobacco dependence, bupropion and nicotine replacement therapy, are effectiv

60 nt differences between the sustained-release bupropion and placebo groups as measured by change in Ar

61 months (the end of the medication phase) for bupropion and placebo, respectively (P =.73).

62 Overall, these negative results with bupropion and risperidone are concordant with previous h

63 ne and placebo nonresponders crossed over to bupropion and sertraline, respectively.

64 nt compounds: the monoamine uptake inhibitor bupropion and the dopamine antagonist risperidone.

65 icotine on response rates in the presence of bupropion and the nAChR antagonist, mecamylamine, as wel

66 <0.001), and 35.5 percent in the group given bupropion and the nicotine patch (P<0.001).

67 Both bupropion and topiramate are widely prescribed drugs.

68 ipiprazole was more effective than switch to bupropion) and severe mixed hypomanic symptoms (for whic

69 6% had nicotine replacement therapy, 28% had bupropion, and 1% had varenicline.

70 While the nicotine lozenge, bupropion, and bupropion plus lozenge produced effects t

71 Lithium, quetiapine, olanzapine, bupropion, and carbamazepine were associated with high m

72 petitive inhibitors: mecamylamine, ketamine, bupropion, and dextromethorphan.

73 A or European Union are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and p

74 Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents tha

75 am, paroxetine, sertraline, venlafaxine, and bupropion, and their metabolites norfluoxetine and norse

76 vior changes associated with varenicline and bupropion, and these drugs' benefits outweigh potential

77 holamine uptake inhibitor and antidepressant bupropion, and this effect of bupropion was reversed by

78 fordability of nicotine replacement therapy, bupropion, and varenicline in the South Indian state of

79 ing cessation (nicotine replacement therapy, bupropion, and varenicline) are effective in patients wi

80 atments (nicotine replacement therapy [NRT], bupropion, and varenicline), which is most effective in

81 tion therapies-nicotine replacement therapy, bupropion, and varenicline-were associated with an incre

82 eation treated with paroxetine compared with bupropion appeared to experience greater acute improveme

83 Both nortriptyline and bupropion are efficacious in producing abstinence in cig

84 gest that clinical and behavioral effects of bupropion arise from actions at nAChR as well as DA and

85 re potent than the (2S,3R) isomer or racemic bupropion as an antagonist of alpha(4)beta(2) (functiona

86 nce the knowledge on the clinical effects of bupropion as an antidepressant.

87 Our meta-analysis suggests varenicline and bupropion, as well as individual and telephone counselin

88 kelihood of smoking cessation in 2 trials of bupropion at 26 weeks (n = 523; 17% [300 mg] and 6% [150

89 55 mg per day) to receive sustained-release bupropion (at a dose of up to 400 mg per day) as augment

90 up, n = 511); augment current treatment with bupropion (augment-bupropion group, n = 506); or augment

91 e 16% with nicotine patch alone and 28% with bupropion augmentation (odds ratio=2.04, 95% CI=1.03-4.0

92 (control condition); "rescue" treatment with bupropion augmentation of the patch; or rescue treatment

93 o precessation nicotine patch benefited from bupropion augmentation; abstinence rates at end of treat

94 er drug candidate for smoking cessation than bupropion because of its higher potency at the relevant

95 ly higher quit rates in intervention groups (bupropion/behavioural support versus placebo in Pakistan

96 was observed among individuals treated with bupropion (beta [SE]: -0.063 [0.027]; P = .02), amitript

97 t was established that both mecamylamine and bupropion block nicotine's rate-reducing effects.

98 gesting either a placebo (pla) or 2 x 300 mg bupropion (bup), prior to exercise in temperate (18 degr

99 ex were associated with positive response to bupropion but not sertraline.

100 , including nicotine replacement therapy and bupropion, can increase cessation rates.

101 Neither behavior-based nor bupropion cessation interventions improved cessation rat

102 ment of unipolar major depression in adults: bupropion, citalopram, duloxetine, escitalopram, fluoxet

103 to another antidepressant-sustained-release bupropion; combination with another antidepressant-susta

104 tte smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased pr

105 ained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treat

106 Bupropion did not initiate abstinence among smokers who

107 Bupropion did not reduce relapse to smoking in smokers w

108 Augmentation with sustained-release bupropion does have certain advantages, including a grea

109 Bupropion doubles quit rates in otherwise healthy smoker

110 en administered in the presence of nicotine, bupropion elicits unique pharmacological differences suc

111 It appears that bupropion enabled subjects to maintain a greater TT powe

112 r pargyline, and the atypical antidepressant bupropion, even though they did not differ in baseline i

113 sights into the pharmacological effects that bupropion exerts on heteromeric 5-HT(3AB) receptors, in

114 tte smokers; however, the mechanism by which bupropion exerts this effect has not yet been described.

115 lication, our findings suggest that prenatal bupropion exposure may be associated with reductions in

116 Collectively, our data indicate that bupropion first binds to the resting AChR, decreasing th

117 may identify patients likely to benefit from bupropion following selective serotonin reuptake inhibit

118 ks of bupropion treatment, sustained-release bupropion for 12 months delayed smoking relapse and resu

119 ychotherapy and adjunctive sustained-release bupropion for nicotine addiction in patients with schizo

120 tment with varenicline and sustained-release bupropion for smokers who, based on an assessment of ini

121 nes for the treatment of sleeping disorders, bupropion for substance abuse disorders, and cannabinoid

122 hese findings suggest that combining CM with bupropion for the treatment of cocaine addiction may sig

123 uture studies should compare higher doses of bupropion for treating sexual dysfunction and should inc

124 RR, 1.19 [95% CI, 1.09-1.29]) or the augment-bupropion group (65.6%; RR, 1.13 [95% CI, 1.04-1.23]).

125 oup and 90 patients (2.0%) in the naltrexone-bupropion group (HR, 0.88; adjusted 99.7% CI, 0.57-1.34)

126 95% CI, 1.91-4.19; P<.001) and 20.2% in the bupropion group (OR, 1.69; 95% CI, 1.19-2.42; P = .003).

127 up, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0001 vs placebo) and -5.0% (0.3) in

128 and -5.0% (0.3) in the naltrexone 16 mg plus bupropion group (p<0.0001 vs placebo).

129 he nicotine-patch group, 30.3 percent in the bupropion group (P<0.001), and 35.5 percent in the group

130 prazole group [n = 84]; and 22.5% in augment-bupropion group [n = 114]).

131 revalence abstinence rates were 37.2% in the bupropion group and 32.0% in the placebo group (p = 0.33

132 The sustained-release bupropion group and the buspirone group had similar rate

133 continuous abstinence rate was higher in the bupropion group than in the placebo group at study week

134 Weight gain was significantly less in the bupropion group than in the placebo group at study weeks

135 g abstinence was significantly higher in the bupropion group than in the placebo group at the end (we

136 e varenicline group, 22 (2.2%) of 989 in the bupropion group, 25 (2.5%) of 1006 in the nicotine patch

137 varenicline group, 68 (6.7%) of 1017 in the bupropion group, 53 (5.2%) of 1016 in the nicotine patch

138 switch group, 26.9% (n = 136)for the augment-bupropion group, and 28.9% (n = 146) for the augment-ari

139 e effects were more common in the naltrexone-bupropion group, including gastrointestinal events in 14

140 nt current treatment with bupropion (augment-bupropion group, n = 506); or augment with an atypical a

141 Anxiety was more frequent in the 2 bupropion groups (24.3% in the switch group [n = 124] vs

142 re also more frequent in the naltrexone plus bupropion groups than in the placebo group.

143 mm Hg below baseline in the naltrexone plus bupropion groups.

144 acement therapy (NRT) and the antidepressant bupropion have been shown to significantly increase cess

145 obacco other than cigarettes; current use of bupropion; having a current psychosis or schizophrenia d

146 nt with either cognitive-behavioral therapy, bupropion HCl, or pill placebo.

147 Sustained-release bupropion, however, was associated with a greater reduct

148 Sustained-release bupropion hydrochloride and nortriptyline hydrochloride

149 iven the actions of varenicline tartrate and bupropion hydrochloride sustained-release (SR) on neurob

150 Bupropion hydrochloride treatment reduces cue-induced cr

151 Sustained-release bupropion hydrochloride was started at 150 mg/d and incr

152 Participants receiving bupropion hydrochloride were given 300 mg/d beginning at

153 pharmacotherapy (paroxetine hydrochloride or bupropion hydrochloride) (n = 88), CBT (n = 90), or comm

154 ined the risk of angle-closure glaucoma with bupropion hydrochloride, a unique, popular antidepressan

155 (eg, nefazodone hydrochloride, mirtazapine, bupropion hydrochloride, and venlafaxine hydrochloride)

156 ption including amitriptyline hydrochloride, bupropion hydrochloride, citalopram hydrobromide, duloxe

157 e non-selective serotonin reuptake inhibitor bupropion hydrochloride, even though it carries the same

158 note response, 76% of the subjects receiving bupropion improved, compared to 37% of the subjects rece

159 ation to determine the anti-ADHD efficacy of bupropion in adult patients with DSM-IV ADHD.

160 Use of bupropion in combination with nicotine replacement thera

161 Use of sustained-release bupropion in combination with supportive group therapy m

162 effective than placebo, nicotine patch, and bupropion in helping smokers achieve abstinence, whereas

163 ally and statistically significant effect of bupropion in improving ADHD in adults.

164 though 2 previous trials examined the use of bupropion in patients hospitalized with acute cardiovasc

165 The results suggest a therapeutic role for bupropion in the armamentarium of agents for ADHD in adu

166 of varenicline relative to both placebo and bupropion, indicating considerable benefit without evide

167 In summary, we demonstrate that bupropion inhibits heteromeric 5-HT(3AB)Rs as well as ho

168 Bupropion interacts with a luminal binding domain shared

169 Bupropion is an atypical antidepressant that also has us

170 Treatment with bupropion is associated with improved ability to resist

171 avioral support alone or in combination with bupropion is effective in promoting cessation in smokers

172 ependent and voltage independent, suggesting bupropion is not an open channel blocker.

173 However, bupropion is not effective for smoking cessation in pati

174 Bupropion is well tolerated and seems to be safe to use

175 ause hydroxybupropion, a major metabolite of bupropion, is believed to contribute to its antidepressa

176 ng safety, serotonin reuptake inhibitors and bupropion may have lower rates of manic switch than tric

177 fic genes, and genes involved in nicotine or bupropion metabolism).

178 onergic-specific (non-SSRI) antidepressants (bupropion, mirtazapine, nefazodone, and venlafaxine), tr

179 eeks of treatment compared with switching to bupropion monotherapy.

180 patch (n=623), nicotine nasal spray (n=189), bupropion (n=213), or placebo (n=192).

181 signed either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-relea

182 receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286).

183 clinical pilot trial of paroxetine (N=36) or bupropion (N=38) in DSM IV major depression with a suici

184 (N=86; sertraline [N=27], sustained-release bupropion [N=28], or extended-release venlafaxine [N=31]

185 medication (N=117; either sustained-release bupropion [N=56] or buspirone [N=61]) or switch to cogni

186 plus bupropion, n=583; naltrexone 16 mg plus bupropion, n=578; placebo, n=581).

187 ouble-blind treatment (naltrexone 32 mg plus bupropion, n=583; naltrexone 16 mg plus bupropion, n=578

188 e lozenge, nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, bupropi

189 Neither bupropion nor varenicline showed an increased risk of an

190 ouped by whether they required augmentation (bupropion, nortriptyline, or lithium) and compared on li

191 ng sites and the mechanisms of inhibition of bupropion on muscle-type nicotinic acetylcholine recepto

192 to receive 8 weeks of treatment with either bupropion or a matching placebo pill (double-blind).

193 epressant or augmentation of citalopram with bupropion or buspirone (second step), adult outpatients

194 of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual cl

195 ne or an augmentation with sustained-release bupropion or buspirone was provided (level 2).

196 Coapplication of bupropion or hydroxybupropion with 5-HT dose dependently

197 her, the effect of in vivo administration of bupropion or mecamylamine on nicotine-stimulated (86)Rb(

198 ceive either 150 mg/day of sustained-release bupropion or placebo at 6:00 p.m. for 3 weeks.

199 participants were eligible to be assigned to bupropion or placebo for 6 months (for relapse preventio

200 participants were eligible to be assigned to bupropion or placebo for 8 weeks of treatment.

201 Participants received bupropion or placebo for 9 weeks and were followed for 1

202 therapy, 3.1% and 0.0% stopped smoking with bupropion or placebo, respectively (P =.12).

203 gned to receive 12 weeks of varenicline plus bupropion or varenicline plus placebo.

204 OR, 2.95; 95% CrI, 2.11-4.23) and naltrexone-bupropion (OR, 2.64; 95% CrI, 2.10-3.35) were associated

205 16-7.78; SUCRA, 0.83), 55% taking naltrexone-bupropion (OR, 3.96; 95% CrI, 3.03-5.11; SUCRA, 0.60), 4

206 er a switch to sertraline, sustained-release bupropion, or extended-release venlafaxine or an augment

207 double-blind 12-week trial of escitalopram, bupropion, or the combination of the two in depressed mo

208 who use nicotine replacement therapy (NRT), bupropion, or varenicline when trying to quit double the

209 on medication (nicotine replacement therapy, bupropion, or varenicline).

210 eplacement treatment (NRT; reference group), bupropion, or varenicline.

211 ith another antidepressant-sustained-release bupropion; or augmentation with an antipsychotic-aripipr

212 226 (48%) assigned to naltrexone 32 mg plus bupropion (p<0.0001 vs placebo) and 186 (39%) assigned t

213 186 (39%) assigned to naltrexone 16 mg plus bupropion (p<0.0001 vs placebo).

214 ese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, comp

215 ce in the heat was significantly improved by bupropion (pla: 39.8 +/- 3.9 min, bup: 36.4 +/- 5.7 min;

216 stigate their role in smoking cessation in a bupropion placebo-controlled randomized clinical trial.

217 The varenicline-placebo and bupropion-placebo RDs were 1.59 (95% CI -0.42 to 3.59) a

218 The varenicline-placebo and bupropion-placebo risk differences (RDs) for moderate an

219 While the nicotine lozenge, bupropion, and bupropion plus lozenge produced effects that were compar

220 opion, nicotine patch plus nicotine lozenge, bupropion plus nicotine lozenge, or placebo.

221 The dopamine reuptake inhibitor bupropion potently inhibited fictive swimming, demonstra

222 istat, phentermine, probably diethylpropion, bupropion, probably fluoxetine, and topiramate promote m

223 , combination treatment with varenicline and bupropion proved more efficacious than varenicline alone

224 Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic

225 than in the acute and continuation trials of bupropion (ratios=0.85 and 1.17, respectively) and sertr

226 ing 21 nicotine replacement therapy RCTs, 28 bupropion RCTs, and 18 varenicline RCTs, we found no inc

227 ime to relapse was significantly greater for bupropion recipients than for placebo recipients (156 da

228 dverse events attributable to varenicline or bupropion relative to nicotine patch or placebo.

229 sk of all cardiovascular disease events with bupropion (relative risk [RR], 0.98; 95% confidence inte

230 scale scores, 52% of the subjects receiving bupropion reported being "much improved" to "very improv

231 Lamotrigine and bupropion represent new treatments for neuropathic pain.

232 rent loci are associated with varenicline vs bupropion response, suggesting that additional research

233 ar events, we found a protective effect with bupropion (RR, 0.45; 95% CI, 0.21-0.85) and no clear evi

234 ement therapy (RR, 1.60 [CI, 1.53 to 1.68]), bupropion (RR, 1.62 [CI, 1.49 to 1.76]), and varenicline

235 95% confidence interval [CI], 1.34-5.21) and bupropion (RR: 1.42; 95% CI, 1.01-2.01) were associated

236 in regions from rats administered 30.0 mg/kg bupropion (s.c.) 15 min prior to dissection compared to

237 elevant concentrations and may contribute to bupropion's clinical effects.

238 tion and/or antidepressants and to elucidate bupropion's possible mechanisms of action(s), 23 analogu

239 The bupropion-selective genes were nominated by bupropion-se

240 bupropion-selective genes were nominated by bupropion-selective results.

241 of 228 acute (10-week) randomized trials of bupropion, sertraline, or venlafaxine as an adjunct to a

242 This result suggests that bupropion shares behavioral effects with mecamylamine wh

243 15 or more cigarettes per day, were assigned bupropion SR (150 mg twice daily) or placebo for 12 week

244 were randomly assigned to receive 150 mg of bupropion SR (n = 300) or placebo (n = 300) twice daily

245 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057).

246 al [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001).

247 enicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]).

248 ling for continuous abstinence, those taking bupropion SR also gained less weight than those taking p

249 Secondary analyses suggest that bupropion SR and cognitive behavioral therapy may be eff

250 ints and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment an

251 Those taking bupropion SR experienced a greater mean reduction in dep

252 95% CI, 1.72-4.11; P<.001) and 14.6% in the bupropion SR group (OR, 1.77; 95% CI, 1.19-2.63; P = .00

253 al [CI], 2.69-5.50; P<.001) and 29.8% in the bupropion SR group (OR, 1.90; 95% CI, 1.38-2.62; P<.001)

254 nd of 7 weeks of treatment were 36.0% in the bupropion SR group and 19.0% in the placebo group (17.0

255 pants in the varenicline group, 12.6% in the bupropion SR group, and 7.3% in the placebo group.

256 Twelve weeks of varenicline and bupropion SR or varenicline and placebo.

257 gnificantly higher in participants receiving bupropion SR than in those receiving placebo (28% [57/20

258 ) were also higher in participants receiving bupropion SR than in those taking placebo (p<0.05).

259 ne titrated to 1 mg twice daily (n = 344) or bupropion SR titrated to 150 mg twice daily (n = 342) or

260 ne titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329),

261 Bupropion SR was also significantly more efficacious tha

262 Bupropion SR was effective for smoking cessation among A

263 Twelve weeks of varenicline, bupropion SR, or placebo plus intensive smoking cessatio

264 m efficacy exceeded that of both placebo and bupropion SR.

265 ithdrawal were attenuated in those receiving bupropion SR.

266 Bupropion SRis a well-tolerated and effective aid to smo

267 among smokers with AMI to determine whether bupropion, started in-hospital, is safe and can improve

268 Switch to a different antidepressant, bupropion (switch group, n = 511); augment current treat

269 e, preincubation with a low concentration of bupropion that mimics therapeutic drug conditions inhibi

270 support sessions (BSS), BSS plus 7 weeks of bupropion therapy (BSS+), or usual care.

271 Adjusted rate ratios were computed for bupropion, topiramate (positive control group drug), and

272 Three other drugs, bupropion, topiramate, and ciliary neurotrophic factor,

273 zine, imipramine, amitriptyline, duloxetine, bupropion, trazodone, tianeptine, and agomelatine.

274 ence of at least one minor (C) allele in the bupropion-treated group (OR=0.43; 95% CI=0.22-0.77; P=0.

275 Bupropion-treated participants reported less craving and

276 bo-treated patients (1.3%) and 35 naltrexone-bupropion-treated patients (0.8%; HR, 0.59; 95% CI, 0.39

277 nt increased methamphetamine choice, whereas bupropion treatment did not alter methamphetamine choice

278 Bupropion treatment was associated with a significant ch

279 At the end of open-label bupropion treatment, 461 of 784 participants (58.8%) wer

280 the 95% CI of the HR for MACE for naltrexone-bupropion treatment, compared with placebo, did not exce

281 persons who stopped smoking with 7 weeks of bupropion treatment, sustained-release bupropion for 12

282 eats min(-1); P = 0.039), were higher in the bupropion trial than in the placebo.

283 In the bupropion trial, smokers carrying the C allele also repo

284 mparing patients receiving sustained-release bupropion (up to 200 mg b.i.d.) (N=21) to patients recei

285 Findings about the harms related to bupropion use were mixed.

286 icotine patch, using varenicline rather than bupropion, using varenicline rather than a nicotine patc

287 nagement vs psychological intervention) x 3 (bupropion vs nortriptyline vs placebo) randomized trial.

288 ctive influences on therapeutic responses to bupropion vs NRT.

289 Chronic and acute use of bupropion was associated with reduced UBF, even after co

290 atment with sustained-release naltrexone and bupropion was developed to produce complementary actions

291 antidepressant bupropion, and this effect of bupropion was reversed by either D1 or D2 family antagon

292 The inhibition by bupropion was reversible and time-dependent.

293 Previously, bupropion was shown to be an antagonist at homopentameri

294 stigation of the efficacy of varenicline and bupropion, we examined whether genes important in the ph

295 In addition, (2S,3S)-hyroxybupropion and bupropion were considerably more potent than (2R, -3R)-h

296 to cocaine, the DAT blockers nomifensine and bupropion were less effective at inhibiting dopamine upt

297 ation with aripiprazole and combination with bupropion were more effective than switch to bupropion).

298 revalence abstinence, both nortriptyline and bupropion were more efficacious than placebo.

299 safety risk and efficacy of varenicline and bupropion with nicotine patch and placebo in smokers wit

300 authors compared low-dose sustained-release bupropion with placebo for sexual dysfunction induced by

301 highest relative risk of such switching and bupropion with the lowest risk.